Sentinel lymph node biopsy after chemotherapy

James W. Jakub, Judy C. Boughey

Research output: Contribution to journalArticlepeer-review


The timing of sentinel lymph node (SLN) biopsy in patients receiving neoadjuvant chemotherapy remains a debated topic, despite increasing literature supporting use of SLN biopsy after chemotherapy. This article outlines the arguments for SLN biopsy prior to initiation of systemic therapy versus after neoadjuvant chemotherapy and the literature surrounding this debate. Additionally, special patient populations, including patients with inflammatory breast cancer and those presenting with node-positive disease, are discussed. SLN biopsy after completion of chemotherapy is accurate for axillary staging of patients with clinically node-negative axillas at presentation, except for those with inflammatory breast cancer.

Original languageEnglish (US)
Pages (from-to)97-103
Number of pages7
JournalCurrent Breast Cancer Reports
Issue number2
StatePublished - Jun 2011


  • Axillary lymph node dissection
  • Breast cancer
  • Inflammatory breast cancer
  • Neoadjuvant chemotherapy
  • Sentinel lymph node biopsy

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Sentinel lymph node biopsy after chemotherapy'. Together they form a unique fingerprint.

Cite this